The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
Students in a private Australian high school have recreated a malaria drug in the school laboratory
2 studies claim psilocybin, outlawed by federal government, could significantly improve patients’ mood
Global crises changing nature of hotel industry, expert warns Mediterranean Week of Economic Leaders conference
Fighting climate change means different things in different cities, as this snapshot illustrates:
The Paris deal, now in force, calls for capping global warming at two degrees Celsius (3.6 degrees Fahrenheit) above pre-industrial levels, and at 1.5 C (2.7 F) if possible.
British MPs voted in February to allow the creation of in-vitro fertilisation (IVF) babies with DNA from three people.
The H5N6 virus was first confirmed on November 18 at a farm in central South Korea and it has since spread to farms around the country, with the total number of cases now standing at 46.
It is one of the biggest clinical trials involving the disease ever undertaken and has revived hopes in the scientific community of a breakthrough in the battle against AIDS.
Nuclear energy: who's advancing and who's retreating
A killer bird flu that is sweeping Europe has forced Sweden to cull more than 200,000 chickens
Study finds blood of old mice makes young mice feeble; scientists hope to discover more in human trials soon
Drug overdoses are now killing more Americans than car crashes, putting the sheer scale of the crisis into perspective.
The idea of clean air, potable water and healthy food free from heavy metals, pesticides, and other pollutants as a human right emerged in the mid-1970s.
60 percent of all Kenyans have never been tested for disease, says report
Average temperatures for the year were set to hit about 1.2 Celsius (2.16 degrees Fahrenheit) over pre-Industrial Revolution levels -- meaning that 16 of the 17 hottest years on record were this century, said the UN's World Meteorological Organization (WMO).